GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (LTS:0A4D) » Definitions » Cash Flow for Lease Financing

Equillium (LTS:0A4D) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Equillium Cash Flow for Lease Financing?

Equillium's Cash Flow for Lease Financing for the three months ended in Mar. 2024 was $0.00 Mil. Equillium's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Dec. 2023 ), Equillium's Cash Flow for Lease Financing remained the same in Mar. 2024 ($0.00 Mil).

Equillium Cash Flow for Lease Financing Historical Data

The historical data trend for Equillium's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium Cash Flow for Lease Financing Chart

Equillium Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow for Lease Financing
Get a 7-Day Free Trial - - - - -

Equillium Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Equillium Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Equillium Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Equillium's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Equillium (LTS:0A4D) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (LTS:0A4D) » Definitions » Cash Flow for Lease Financing
Comparable Companies
PMCB TCRT FBRX IGC AKTX AVTX MYMD KALA ENTX INDP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
EQ:USA 0FY:Germany
Address
2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037
Website
https://www.equilliumbio.com
Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Equillium (LTS:0A4D) Headlines

No Headlines